PASG on Nasdaq

Passage BIO, Inc.

We are a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerPASG on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersPhiladelphia, Pennsylvania1
  • Incorporated inDE2
  • Business addressOne Commerce Square, 2005 Market Street, 39Th Floor, Philadelphia, Pa 191032
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. We believe we have developed a differentiated approach to developing treatments for central nervous system, or CNS, disorders that allows us to select and advance product candidates with a higher probability of technical and regulatory success.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$49.3M in 2025+33% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$37.2M-$37.2M20192020: -$112.9M-$112.9M2020+204%2021: -$185.7M-$185.7M2021+65%2022: -$138.4M-$138.4M2022−25%2023: -$108.4M-$108.4M2023−22%2024: -$70.4M-$70.4M2024−35%2025: -$49.3M-$49.3M2025−30%
Net income456789-$45.5M in 2025−0% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$45.6M-$45.6M20192020: -$112.2M-$112.2M2020+146%2021: -$185.4M-$185.4M2021+65%2022: -$136.1M-$136.1M2022−27%2023: -$102.1M-$102.1M2023−25%2024: -$64.8M-$64.8M2024−37%2025: -$45.5M-$45.5M2025−30%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development$23.3M$40.2M
General and administrative$19.9M$25.0M
Impairment of long-lived assets$6.1M$5.2M
Loss from operations-$49.3M-$70.4M
Other income (expense), net$3.8M$5.6M
Net loss-$45.5M-$64.8M
Net loss per share of common stock, basic-$14.35-$21.04
Net loss per share of common stock, diluted-$14.35-$21.04
Weighted average common shares outstanding, basic3.2M shares3.1M shares
Weighted average common shares outstanding, diluted3.2M shares3.1M shares
Unrealized gain (loss) on marketable securities-$8.0K$51.0K
Comprehensive loss-$45.5M-$64.7M

Compare Passage BIO, Inc. with another company

Leadership

Who has led Passage BIO, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Edgar B. Cale2022
  2. William Chou2022–now

President

  1. William Chou2023–now

Chief financial officer

  1. Richard Steven Morris2020–2021
  2. Kathleen Borthwick2023–now

Chief operating officer

  1. Jill M. Quigley2020–2021
2025
Board members and other officers (22)

Timeline

  1. Oct 12, 2022New chief executive William Chou becomes CEO13
  2. Jun 1, 2022New chief executive Edgar B. Cale becomes CEO12

Filings

294 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 69 major events, 118 insider forms, 34 large holders, 53 other. The latest 20:

  1. Oct 9, 2026EFFECT EDGAR
  2. Oct 9, 2026424B3 EDGAR
  3. Oct 8, 2026S-4/A EDGAR
  4. Oct 5, 2026S-4/A EDGAR
  5. Sep 21, 2026S-4/A EDGAR
  6. Sep 3, 2026S-4/A S-4A EDGAR
  7. Sep 3, 2026425 EDGAR
  8. Sep 3, 20268-K EDGAR
  9. Aug 14, 2026SCHEDULE 13G/A EDGAR
  10. Aug 10, 202610-Q EDGAR
  11. Jul 22, 2026425 EDGAR
  12. Jul 21, 2026S-4 EDGAR
  13. Jul 2, 2026SCHEDULE 13D EDGAR
  14. Jun 29, 20264 EDGAR
  15. Jun 25, 2026SCHEDULE 13G EDGAR
  16. Jun 24, 2026425 EDGAR
  17. Jun 24, 2026425 EDGAR
  18. Jun 24, 20268-K EDGAR
  19. May 27, 20268-K EDGAR
  20. May 26, 20268-K EDGAR

The 294 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

63 open-market trades by officers, directors and large owners since October 2021: 24 buys and 39 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 25, 2026Nichols Weston10% ownerBuy50,055$4.12$206.2KForm 4
Jan 8, 2026Borthwick KathleenCFOSale2,062$18.44$38.0KForm 4
Jan 8, 2026Chou WilliamPRESIDENT AND CEOSale4,076$18.44$75.2KForm 4
Sep 15, 2025Nichols Weston10% ownerBuy11,900$6.99$83.2KForm 4
Sep 12, 2025Nichols Weston10% ownerBuy19,783$6.99$138.3KForm 4
Sep 11, 2025Nichols Weston10% ownerBuy325$6.96$2.3KForm 4
Jul 24, 2025Lynx1 Capital Management LP10% ownerBuy66,423$5.71$379.3KForm 4
Jul 23, 2025Lynx1 Capital Management LP10% ownerBuy49,302$5.74$283.0KForm 4
Jul 22, 2025Lynx1 Capital Management LP10% ownerBuy13,123$5.44$71.4KForm 4
Jun 26, 2025ORBIMED ADVISORS LLC10% ownerSale213,257$0.33$70.4KForm 4
Jun 25, 2025ORBIMED ADVISORS LLC10% ownerSale138,800$0.33$45.8KForm 4
Jun 24, 2025ORBIMED ADVISORS LLC10% ownerSale231,600$0.35$81.1KForm 4
Apr 24, 2025ORBIMED ADVISORS LLC10% ownerSale68,195$0.32$21.8KForm 4
Apr 23, 2025ORBIMED ADVISORS LLC10% ownerSale89,328$0.34$30.4KForm 4
Apr 22, 2025ORBIMED ADVISORS LLC10% ownerSale78,049$0.34$26.5KForm 4
Apr 17, 2025OrbiMed Capital GP VII LLC10% ownerSale77,090$0.33$25.4KForm 4
Apr 16, 2025OrbiMed Capital GP VII LLC10% ownerSale61,638$0.33$20.3KForm 4
Apr 15, 2025OrbiMed Capital GP VII LLC10% ownerSale10,326$0.38$3.9KForm 4
Feb 11, 2025Borthwick KathleenCFOSale3,183$0.53$1.7KForm 4
Jan 14, 2025ORBIMED ADVISORS LLC10% ownerSale79,024$0.60$47.4KForm 4

All 63 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 29. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC2,886,125$4.3M0.0%New
Lynx1 Capital Management LP673,759$3.3M0.4%+50,055
Vanguard Capital Management LLC113,964$556.1K0.0%No change
Balyasny Asset Management L.P.107,025$522.3K0.0%New
Ikarian Capital, LLC99,517$485.6K0.1%+31,393
Yiheng Capital Management, L.P.86,097$420.2K0.2%No change
Renaissance Technologies LLC47,892$233.7K0.0%−85,720
Erste Asset Management GmbH40,665$197.2K0.0%−44,597
Geode Capital Management, LLC37,026$180.7K0.0%−4,354
Verdad Advisers, LP30,728$150.0K0.1%+8,600
Boothbay Fund Management, LLC28,439$138.8K0.0%+9,568
BlackRock, Inc.27,910$136.2K0.0%−685
Vanguard Fiduciary Trust Co17,049$83.2K0.0%No change
Deltec Asset Management LLC15,000$73.2K0.0%New
UBS Group AG13,565$66.2K0.0%−13,936
Fiduciary Trust Co10,750$52.5K0.0%No change
Gts Securities LLC10,000$48.8K0.0%New
Morgan Stanley2,389$11.7K0.0%−261
Vanguard Global Advisers, LLC638$3.1K0.0%No change
Barclays PLC212$1.0K0.0%No change
SBI Securities Co., Ltd.169$8250.0%+45
Wells Fargo & Company/mn115$5610.0%No change
Acadian Asset Management LLC22,496$1090.0%−1,700
Jpmorgan Chase & Co15$730.0%No change
Osaic Holdings, Inc.15$730.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48